NCT05171777 is a Phase 2 clinical trial of Atezolizumab in Non-small Cell Lung Cancer, sponsored by Hoffmann-La Roche.

Who is sponsoring NCT05171777?

NCT05171777 is sponsored by Hoffmann-La Roche.

What drugs are being tested in NCT05171777?

Interventions in NCT05171777: Atezolizumab.

What condition does NCT05171777 study?

NCT05171777 studies Non-small Cell Lung Cancer.

Is NCT05171777 still recruiting?

NCT05171777 is currently completed. Last updated 11 December 2025.

Are results published for NCT05171777?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-12-11 · How we verify

NCT05171777

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer

Completed Phase 2 Results posted Last updated 11 December 2025

What this trial tests

Phase 2 trial testing Atezolizumab in Non-small Cell Lung Cancer in 179 participants. Completed in 25 October 2024.

Timeline

4 April 2022

Primary endpoint
9 November 2023

25 October 2024

Quick facts

Lead sponsor	Hoffmann-La Roche
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	179
Start date	4 April 2022
Primary completion	9 November 2023
Estimated completion	25 October 2024
Sites	36 locations across Italy, Costa Rica, Finland, Chile, Poland, South Korea, Argentina, Canada

Drugs / interventions tested

Atezolizumab (atezolizumab) — full drug profile →

Conditions studied

Non-small Cell Lung Cancer — all drugs for Non-small Cell Lung Cancer →

Sponsor

Hoffmann-La Roche — full company profile →

Who can join

18 and older, any sex, with Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Percentage of Participants Who Preferred Atezolizumab SC to Atezolizumab IV Assessed Using Patient Preference Questionnaire (PPQ) Primary · Cycle 6 Day 1 (cycle length=21 days)

Participants preference was assessed based on the Question 1 of PPQ. Question 1 (All things considered, which route of administration did you prefer?) asks participants to report their preference for the route of administration (IV, SC, or no preference). A point estimate with associated 95% CI for the percentage of participants who preferred atezolizumab SC was calculated. Participants experiencing any of the following events: treatment withdrawal prior to eligibility for PPQ, or death without answering Question 1 of PPQ, or treatment not started; were excluded from the analysis set. Particip

Group	Value	95% CI
Crossover Atezolizumab IV/SC	71.67	58.56 – 82.55
Crossover Atezolizumab SC/IV	69.84	56.98 – 80.77
All Participants	70.73	61.85 – 78.59

Number of Participants by Their Level of Satisfaction With Atezolizumab SC and Atezolizumab IV Assessed Using Therapy Administration Satisfaction Questionnaire - Subcutaneous (TASQ-SC) and Intravenous (TASQ-IV) Secondary · Cycles 3 Day 1 and Cycle 6 Day 1 (cycle length=21 days)

TASQ is a 12-item, participant-reported questionnaire measuring the impact of each mode of treatment administration (TASQ-IV for IV treatment and TASQ-SC for SC treatment) on five domains: Physical Impact, Psychological Impact, Impact on Activities of Daily Living, Convenience, and Satisfaction. TASQ-IV/-SC was administered at treatment Cycles 3 and 6 according to the order of treatment received per arm during the Crossover Period. Participants satisfaction was assessed based on the Question 1 of TASQ-IV/SC which asks participants about their satisfaction with respect to route of administratio

TASQ- IV- Very Satisfied

Group	Value	95% CI
Crossover Atezolizumab IV/SC	25
Crossover Atezolizumab SC/IV	10

TASQ- IV- Satisfied

Group	Value	95% CI
Crossover Atezolizumab IV/SC	31
Crossover Atezolizumab SC/IV	34

TASQ- IV- Neither Satisfied nor Dissatisfied

Group	Value	95% CI
Crossover Atezolizumab IV/SC	17
Crossover Atezolizumab SC/IV	11

TASQ- IV- Dissatisfied

Group	Value	95% CI
Crossover Atezolizumab IV/SC	1
Crossover Atezolizumab SC/IV	1

TASQ- IV- Very Dissatisfied

Group	Value	95% CI
Crossover Atezolizumab IV/SC	0
Crossover Atezolizumab SC/IV	3

TASQ- IV- Participant did not Answer Question

Group	Value	95% CI
Crossover Atezolizumab IV/SC	0
Crossover Atezolizumab SC/IV	0

TASQ- SC- Very Satisfied

Group	Value	95% CI
Crossover Atezolizumab IV/SC	22
Crossover Atezolizumab SC/IV	30

TASQ- SC- Satisfied

Group	Value	95% CI
Crossover Atezolizumab IV/SC	21
Crossover Atezolizumab SC/IV	36

Percentage of Participants Who Select Atezolizumab SC for Treatment Continuation Period Secondary · Cycle 6 Day 1 (Cycle length=21 days)

At Cycle 6, Day 1, participants were expected to select the route of study treatment administration (SC or IV) they would like to receive during the Treatment Continuation Period (starting at Cycle 7). Percentage of participants who chose SC administration have been reported here. Percentages have been rounded off.

Group	Value	95% CI
Crossover Atezolizumab IV/SC	78.2
Crossover Atezolizumab SC/IV	76.7

Duration of Treatment Preparation According to Healthcare Professionals (HCPs) Response to Perception of Time, Assessed Using Question 1 of Healthcare Professional Questionnaires (HCPQs) - Drug Preparation Area Secondary · Day 1 of Cycles 1 to 6 (cycle length= 21 days)

The HCPQ- Drug Preparation Area Question 1 was completed by the HCPs within the pharmacy/drug preparation area where atezolizumab IV reconstitution or atezolizumab SC was prepared before the actual drug administration took place. The HCPQs were completed for every participant at each treatment cycle (Cycles 1-6, i.e., 3 cycles of atezolizumab IV followed by 3 cycles of atezolizumab SC or vice versa) of the treatment cross-over period. HCPs responded to the following parts of Question 1 that sought to evaluate the amount of time it took to prepare the IV infusion/SC injection of atezolizumab: "

Cycle 1

Group	Value	95% CI
Atezolizumab IV/SC	5.0	1 – 40
Atezolizumab SC/IV	5.0	1 – 45

Cycle 2

Group	Value	95% CI
Atezolizumab IV/SC	5.0	1 – 40
Atezolizumab SC/IV	5.0	1 – 35

Cycle 3

Group	Value	95% CI
Atezolizumab IV/SC	5.0	1 – 45
Atezolizumab SC/IV	4.5	1 – 40

Cycle 4

Group	Value	95% CI
Atezolizumab IV/SC	5.0	1 – 35
Atezolizumab SC/IV	5.0	1 – 50

Cycle 5

Group	Value	95% CI
Atezolizumab IV/SC	5.0	1 – 35
Atezolizumab SC/IV	5.0	1 – 59

Cycle 6

Group	Value	95% CI
Atezolizumab IV/SC	5.0	1 – 35
Atezolizumab SC/IV	5.0	1 – 36

Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area Secondary · Cycle 6 Day 1 (cycle length=21 days)

HCPs within pharmacy/drug preparation area responded to HCPQ-Drug Preparation Area Question 2 at Cycle 6 of Treatment Crossover Period for every participant: "If all IV infusions are switched to SC, please indicate how strongly you agree/disagree with each of following statements: a=Staff will have increased availability for other tasks in pharmacy; b=Administrative procedures around atezolizumab SC will require less time; c=Atezolizumab SC formulations will provide more flexibility for staff in managing their workload; d=Due to ready-to-use atezolizumab SC formulations, potential dosing error

a=Strongly Disagree

Group	Value	95% CI
Atezolizumab IV/ SC	7.0
Atezolizumab SC/ IV	10.0

a=Disagree

Group	Value	95% CI
Atezolizumab IV/ SC	7.0
Atezolizumab SC/ IV	0

a=Neutral

Group	Value	95% CI
Atezolizumab IV/ SC	21.1
Atezolizumab SC/ IV	31.7

a=Agree

Group	Value	95% CI
Atezolizumab IV/ SC	24.6
Atezolizumab SC/ IV	20.0

a=Strongly Agree

Group	Value	95% CI
Atezolizumab IV/ SC	31.6
Atezolizumab SC/ IV	25.0

a=Not Applicable

Group	Value	95% CI
Atezolizumab IV/ SC	3.5
Atezolizumab SC/ IV	1.7

a=Missing

Group	Value	95% CI
Atezolizumab IV/ SC	5.3
Atezolizumab SC/ IV	11.7

b=Strongly Disagree

Group	Value	95% CI
Atezolizumab IV/ SC	7.0
Atezolizumab SC/ IV	10.0

Percentage of HCPs by Their Response to Perception of Time/Resource Use for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 and 4 of HCPQ - Drug Preparation Area Secondary · Cycle 6 Day 1 (cycle length= 21 days)

HCPs who prepared study treatment within the pharmacy/drug preparation area responded at to the following HCPQ-Drug Preparation Area Questions 3 and 4, at Cycle 6 of the Treatment Crossover Period for every participant: "Looking back over the Atezolizumab treatment sessions, please indicate based on your opinion which administration method: Question 3. Was quickest from start to end of preparation to finish of administration (excluding observation period)?; Question 4. Required less resource use for preparation and administration, for example nursing time, facility costs, equipment etc?" The f

Question 3=Atezolizumab SC

Group	Value	95% CI
Atezolizumab IV/ SC	71.9
Atezolizumab SC/ IV	58.3

Question 3=Atezolizumab IV

Group	Value	95% CI
Atezolizumab IV/ SC	0
Atezolizumab SC/ IV	0

Question 3=No Difference

Group	Value	95% CI
Atezolizumab IV/ SC	17.5
Atezolizumab SC/ IV	21.7

Question 3=Missing

Group	Value	95% CI
Atezolizumab IV/ SC	10.5
Atezolizumab SC/ IV	20.0

Question 4=Atezolizumab SC

Group	Value	95% CI
Atezolizumab IV/ SC	64.9
Atezolizumab SC/ IV	60.0

Question 4=Atezolizumab IV

Group	Value	95% CI
Atezolizumab IV/ SC	3.5
Atezolizumab SC/ IV	0

Question 4=No Difference

Group	Value	95% CI
Atezolizumab IV/ SC	21.1
Atezolizumab SC/ IV	20.0

Question 4=Missing

Group	Value	95% CI
Atezolizumab IV/ SC	10.5
Atezolizumab SC/ IV	20.0

Duration of Treatment Administration Activities According to HCPs Response to Perception of Time, Assessed Using Question 1 of HCPQs - Treatment Room Secondary · Day 1 of Cycles 1 to 6 (cycle length=21 days)

The HCPQ-Treatment Room Question 1 was completed for every participant at each treatment cycle of the Treatment Crossover Period (Cycles 1-6,i.e., 3 cycles of atezolizumab IV followed by 3 cycles of atezolizumab SC/vice versa) by HCPs who administered treatment to the study participants. HCPs responded to following parts of Question 1 that sought to evaluate the amount of time it took to complete activities related to treatment administration: "If new IV access was needed for this cycle of treatment, please indicate what type of IV access was provided (central venous catheter, peripherally ins

Cycle 1: Duration of Central Venous Catheter set up?

Group	Value	95% CI
Atezolizumab IV/ SC	5	5 – 5

Cycle 1: Duration of Peripherally Inserted Central Catheter set up?

Group	Value	95% CI
Atezolizumab IV/ SC	30.0	8 – 30

Cycle 1: Duration of Peripheral Vein Cannulation set up?

Group	Value	95% CI
Atezolizumab IV/ SC	5.0	1 – 70

Cycle 1: How Long did it Take to Administer the Treatment?

Group	Value	95% CI
Atezolizumab IV/ SC	60.0	10 – 120
Atezolizumab SC/ IV	8.0	5 – 75

Cycle 1: How Long was the Participant in the Treatment Room in Total?

Group	Value	95% CI
Atezolizumab IV/ SC	92.0	35 – 390
Atezolizumab SC/ IV	55.0	10 – 260

Cycle 2: Duration of Peripherally Inserted Central Catheter set up?

Group	Value	95% CI
Atezolizumab IV/ SC	30.0	5 – 35

Cycle 2: Duration of Peripheral Vein Cannulation set up?

Group	Value	95% CI
Atezolizumab IV/ SC	5.0	3.0 – 10.0

Cycle 2: How Long did it Take to Administer the Treatment?

Group	Value	95% CI
Atezolizumab IV/ SC	30.0	13 – 90
Atezolizumab SC/ IV	6.0	3 – 30

Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room Secondary · Cycle 6 Day 1 (cycle length=21 days)

HCPs who administered treatment responded to Question 2: If all IV are switched to SC, please indicate how strongly you agree/disagree with each of following statements: a= Participants will be moved outside of infusion unit to receive SC injections (physician consultation room); b=Atezolizumab SC route will allow more flexible treatment scheduling; c=More participants will be treated in infusion unit; d=Waiting list for any IV treatment at infusion unit will be reduced; e=Staff resources will be re distributed to other departments of the hospital (less staffing required within infusion unit);

a=Strongly Disagree

Group	Value	95% CI
Atezolizumab IV/SC	13.8
Atezolizumab SC/ IV	11.5

a=Disagree

Group	Value	95% CI
Atezolizumab IV/SC	15.5
Atezolizumab SC/ IV	23.0

a=Neutral

Group	Value	95% CI
Atezolizumab IV/SC	1.7
Atezolizumab SC/ IV	6.6

a=Agree

Group	Value	95% CI
Atezolizumab IV/SC	27.6
Atezolizumab SC/ IV	23.0

a=Strongly Agree

Group	Value	95% CI
Atezolizumab IV/SC	17.2
Atezolizumab SC/ IV	14.8

a=Not Applicable

Group	Value	95% CI
Atezolizumab IV/SC	10.3
Atezolizumab SC/ IV	1.6

a=Missing

Group	Value	95% CI
Atezolizumab IV/SC	13.8
Atezolizumab SC/ IV	19.7

b=Strongly Disagree

Group	Value	95% CI
Atezolizumab IV/SC	5.3
Atezolizumab SC/ IV	1.6

Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room Secondary · Cycle 6 Day 1 (cycle length=21 days)

HCPs who administered study treatment responded at Cycle 6 of the Treatment Crossover Period to the following HCPQ-treatment room Questions 3 to 7: "Looking back over the atezolizumab treatment sessions, please indicate based on your opinion which administration method: Question 3. Which method was most convenient for the participant? Question 4. Which method was best for optimizing participant care in your center? Question 5. Which method took the least time from start to finish of administration? Question 6. Which method required the least resource use for administration? Question 7. Which m

Q3=Atezolizumab SC

Group	Value	95% CI
Atezolizumab IV/ SC	72.4
Atezolizumab SC/ IV	63.9

Q3=Atezolizumab IV

Group	Value	95% CI
Atezolizumab IV/ SC	5.2
Atezolizumab SC/ IV	10.1

Q3=No Difference

Group	Value	95% CI
Atezolizumab IV/ SC	6.9
Atezolizumab SC/ IV	8.4

Q3=Unsure

Group	Value	95% CI
Atezolizumab IV/ SC	1.7
Atezolizumab SC/ IV	3.3

Q3= Missing

Group	Value	95% CI
Atezolizumab IV/ SC	13.8
Atezolizumab SC/ IV	14.4

Q4=Atezolizumab SC

Group	Value	95% CI
Atezolizumab IV/ SC	55.2
Atezolizumab SC/ IV	39.3

Q4=Atezolizumab IV

Group	Value	95% CI
Atezolizumab IV/ SC	6.9
Atezolizumab SC/ IV	1.5

Q4=No Difference

Group	Value	95% CI
Atezolizumab IV/ SC	20.7
Atezolizumab SC/ IV	31.1

Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 8 of HCPQ - Treatment Room Secondary · Cycle 6 Day 1 (cycle length= 21 days)

HCPs who administered study treatment responded at Cycle 6 of the treatment Cross-over Period to the following HCPQ-treatment room Question 8: How frequently would you offer or recommend atezolizumab SC administration to your participants in the future? The four available response options were Always, Sometimes, Never and Missing. Percentages have been rounded off.

Question 8=Always

Group	Value	95% CI
Atezolizumab IV/ SC	41.4
Atezolizumab SC/ IV	31.1

Question 8=Sometimes

Group	Value	95% CI
Atezolizumab IV/ SC	34.5
Atezolizumab SC/ IV	37.7

Question 8=Never

Group	Value	95% CI
Atezolizumab IV/ SC	10.3
Atezolizumab SC/ IV	14.8

Question 8=Missing

Group	Value	95% CI
Atezolizumab IV/ SC	13.8
Atezolizumab SC/ IV	16.4

Change From Baseline Over Time in Physical Functioning Scale Score as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC-QLQ-C30) Secondary · Baseline, Day 1 of Cycles 3, 6, 7, 10, 13, 16 and End of Treatment (up to approximately 2.2 years)

EORTC QLQ-C30 consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), global health status (GHS) and quality of life (QoL), and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) with a recall period of the previous week. Scale scores can be obtained for the multi-item scales. The functioning items are scored on a 4-point scale (1=Not at All to 4=Very Much). Scores are linearly transformed on a scale of 0 to

Baseline

Group	Value	95% CI
Crossover Atezolizumab IV/SC	75.00	± 19.79
Crossover Atezolizumab SC/IV	72.09	± 20.10

Change at Cycle 3 Day 1

Group	Value	95% CI
Crossover Atezolizumab IV/SC	-0.46	± 19.62
Crossover Atezolizumab SC/IV	-2.01	± 16.00

Change at Cycle 6 Day 1

Group	Value	95% CI
Crossover Atezolizumab IV/SC	0.00	± 16.19
Crossover Atezolizumab SC/IV	-1.60	± 16.74

Change at Cycle 7 Day 1

Group	Value	95% CI
Continuation Atezolizumab IV	-2.22	± 13.85
Continuation Atezolizumab SC	0.03	± 15.39

Change at Cycle 10 Day 1

Group	Value	95% CI
Continuation Atezolizumab IV	0.91	± 19.55
Continuation Atezolizumab SC	2.06	± 16.64

Change at Cycle 13 Day 1

Group	Value	95% CI
Continuation Atezolizumab IV	-5.10	± 19.93
Continuation Atezolizumab SC	-0.43	± 17.98

Change at Cycle 16 Day 1

Group	Value	95% CI
Continuation Atezolizumab IV	0.48	± 16.22
Continuation Atezolizumab SC	1.03	± 15.77

Change at End of Treatment

Group	Value	95% CI
Crossover Atezolizumab IV/SC	-13.75	± 28.39
Crossover Atezolizumab SC/IV	-14.67	± 25.49
Continuation Atezolizumab IV	-8.06	± 21.26
Continuation Atezolizumab SC	-3.92	± 21.67

Change From Baseline Over Time in Role Functioning Scale Score as Assessed by EORTC-QLQ-C30 Secondary · Baseline, Day 1 of Cycles 3, 6, 7, 10, 13, 16 and End of Treatment (up to approximately 2.2 years)

EORTC QLQ-C30 consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), GHS and QoL, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) with a recall period of the previous week. Scale scores can be obtained for the multi-item scales. The functioning items are scored on a 4-point scale (1=Not at All to 4=Very Much). Scores are linearly transformed on a scale of 0 to 100, with a high score indicating better

Baseline

Group	Value	95% CI
Crossover Atezolizumab IV/SC	77.46	± 25.15
Crossover Atezolizumab SC/IV	73.73	± 27.86

Change at Cycle 3 Day 1

Group	Value	95% CI
Crossover Atezolizumab IV/SC	1.16	± 29.25
Crossover Atezolizumab SC/IV	-1.33	± 21.88

Change at Cycle 6 Day 1

Group	Value	95% CI
Crossover Atezolizumab IV/SC	-2.01	± 26.13
Crossover Atezolizumab SC/IV	-1.64	± 24.10

Change at Cycle 7 Day 1

Group	Value	95% CI
Continuation Atezolizumab IV	-8.33	± 18.39
Continuation Atezolizumab SC	-5.41	± 26.00

Change at Cycle 10 Day 1

Group	Value	95% CI
Continuation Atezolizumab IV	-6.82	± 23.94
Continuation Atezolizumab SC	-2.03	± 24.20

Change at Cycle 13 Day 1

Group	Value	95% CI
Continuation Atezolizumab IV	-6.86	± 21.29
Continuation Atezolizumab SC	-1.60	± 26.52

Change at Cycle 16 Day 1

Group	Value	95% CI
Continuation Atezolizumab IV	-2.38	± 14.41
Continuation Atezolizumab SC	-2.74	± 26.84

Change at End of Treatment

Group	Value	95% CI
Crossover Atezolizumab IV/SC	-16.67	± 43.81
Crossover Atezolizumab SC/IV	-15.00	± 24.15
Continuation Atezolizumab IV	-9.72	± 24.04
Continuation Atezolizumab SC	-8.01	± 25.88

Adverse events — posted to ClinicalTrials.gov

Time frame: Up to 90 days after the final dose of study drug (Up to 2.4 years). Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Crossover Atezolizumab IV

Serious: 15/160 (9%)

Deaths: 16/160

Crossover Atezolizumab SC

Serious: 13/155 (8%)

Deaths: 21/155

Continuation Atezolizumab IV

Serious: 6/26 (23%)

Deaths: 5/26

Continuation Atezolizumab SC

Serious: 12/89 (13%)

Deaths: 12/89

All Participants

Serious: 45/175 (26%)

Deaths: 54/175

Serious adverse events (55 terms)

Reaction	System	Crossover Atezolizumab IV	Crossover Atezolizumab SC	Continuation Atezolizumab IV	Continuation Atezolizumab SC	All Participants
Pneumonia bacterial	Infections and infestations	—	—	—	—	—
Pneumonia	Infections and infestations	—	—	—	—	—
Lower respiratory tract infection	Infections and infestations	—	—	—	—	—
Respiratory failure	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—
Atrial fibrillation	Cardiac disorders	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—
Infusion related reaction	Injury, poisoning and procedural complications	—	—	—	—	—
Cerebrovascular accident	Nervous system disorders	—	—	—	—	—
Immune-mediated encephalitis	Nervous system disorders	—	—	—	—	—
Acute kidney injury	Renal and urinary disorders	—	—	—	—	—
Haemoptysis	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—
Pulmonary embolism	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—
Acute myocardial infarction	Cardiac disorders	—	—	—	—	—
Angina pectoris	Cardiac disorders	—	—	—	—	—
Autoimmune myocarditis	Cardiac disorders	—	—	—	—	—
Cardiac failure congestive	Cardiac disorders	—	—	—	—	—
Cardiac tamponade	Cardiac disorders	—	—	—	—	—
Immune-mediated myocarditis	Cardiac disorders	—	—	—	—	—
Colitis	Gastrointestinal disorders	—	—	—	—	—
Dysphagia	Gastrointestinal disorders	—	—	—	—	—
Immune-mediated enterocolitis	Gastrointestinal disorders	—	—	—	—	—
Pain	General disorders	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—
Bronchitis	Infections and infestations	—	—	—	—	—
COVID-19	Infections and infestations	—	—	—	—	—

Other adverse events (19 terms — click to expand)

Reaction	System	Crossover Atezolizumab IV	Crossover Atezolizumab SC	Continuation Atezolizumab IV	Continuation Atezolizumab SC	All Participants
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—
Asthenia	General disorders	—	—	—	—	—
Pruritus	Skin and subcutaneous tissue disorders	—	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—
Injection site reaction	General disorders	—	—	—	—	—
Rash	Skin and subcutaneous tissue disorders	—	—	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—
Blood creatinine increased	Investigations	—	—	—	—	—
Arthralgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—
Fatigue	General disorders	—	—	—	—	—
Hypothyroidism	Endocrine disorders	—	—	—	—	—
COVID-19	Infections and infestations	—	—	—	—	—
Decreased appetite	Metabolism and nutrition disorders	—	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—	—
Bronchitis	Infections and infestations	—	—	—	—	—
Pain in extremity	Musculoskeletal and connective tissue disorders	—	—	—	—	—
Upper respiratory tract infection	Infections and infestations	—	—	—	—	—
Dizziness	Nervous system disorders	—	—	—	—	—
Conjunctivitis	Infections and infestations	—	—	—	—	—

Most-reported serious reactions: Pneumonia bacterial, Pneumonia, Lower respiratory tract infection, Respiratory failure, Atrial fibrillation, Vomiting, Infusion related reaction, Cerebrovascular accident.

Data from ClinicalTrials.gov NCT05171777 adverse events section.

Sponsor's own description

This is a Phase II, randomized, multi-center, multinational, open-label, cross-over study in adult participants with PD-L1-positive NSCLC. Two populations will be included: participants with resected Stage II, IIIA, and selected IIIB (T3-N2) NSCLC who have completed adjuvant platinum-based chemotherapy without evidence of disease relapse/recurrence, and chemotherapy-naïve participants with Stage IV NSCLC. The study will evaluate participant- and healthcare professionals (HCP)-reported preference for atezolizumab subcutaneous (SC) compared with atezolizumab intravenous (IV).

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Primary Results from IMscin002: A Study to Evaluate Patient Preferences and Perceptions of Health Care Professionals for Atezolizumab Subcutaneous Versus Intravenous for the Treatment of NSCLC.
Cappuzzo F, Zvirbule Z, Korbenfeld E, Kolb-Sielecki J, et al · · 2025 · cited 4× · PMID 40248457 · DOI 10.1016/j.jtocrr.2025.100815
Assessing the impact of digital patient monitoring on health outcomes and healthcare resource usage in addition to the feasibility of its combination with at-home treatment, in participants receiving systemic anticancer treatment in clinical practice: protocol for an intervention
Iivanainen S, Baird AM, Balas B, Bustillos A, et al · · 2023 · cited 3× · PMID 37076159 · DOI 10.1136/bmjopen-2022-063242
Efficacy and safety of subcutaneous and intravenous administration of atezolizumab in patients with non-small cell lung cancer, including early-stage, locally advanced or metastatic disease: Updated results of the IMscin001 and IMscin002 randomized studies.
Burotto M, Zvirbule Z, Alvarez R, Chewaskulyong B, et al · · 2026 · PMID 42214243 · DOI 10.1016/j.lungcan.2026.109452
Exploratory Analyses of Patient Preferences for Atezolizumab Subcutaneous Versus Intravenous from the IMscin002 Study in Patients with Non-Small Cell Lung Cancer.
Majem M, Chewaskulyong B, Zvirbule Z, Lee KH, et al · · 2026 · PMID 41296193 · DOI 10.1007/s40487-025-00402-x
ICTIS: A Novel Scoring System to Assess the Inclusivity of Advanced NSCLC Immunotherapy Trials.
Nguyen K, Wei A, Govindan S, Oduah E, et al · · 2025 · PMID 41245308 · DOI 10.1016/j.jtocrr.2025.100878

Verify or expand the search:

Other trials of Atezolizumab

Trials testing the same drug.

NCT07388524 — Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer · Phase 3 · not yet recruiting
NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07339059 — Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Ce · Phase 2 · recruiting
NCT07461675 — Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resec · Phase 3 · not yet recruiting
NCT07291076 — A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants Wit · Phase 1, PHASE2 · recruiting

Other recruiting trials for Non-small Cell Lung Cancer

Currently open trials in the same condition.

NCT07431827 — MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) · Phase 3 · recruiting
NCT05987956 — Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms · Phase 2, PHASE3 · active not recruiting
NCT07195695 — Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer Wit · Phase 3 · recruiting
NCT06686771 — Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer · Phase 3 · recruiting
NCT06477055 — The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer · recruiting

Other Hoffmann-La Roche trials

Trials by the same sponsor.

NCT07503340 — A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous O · Phase 2 · not yet recruiting
NCT07298421 — A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in · Phase 3 · recruiting
NCT07059273 — A COPD Data Registry for Participants With Frequent Exacerbations · not yet recruiting
NCT07416526 — A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A · Phase 3 · recruiting
NCT05199688 — A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05171777 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hoffmann-La Roche
Last refreshed: 11 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05171777.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing